Actively Recruiting
Open-Label Clinical Trial Evaluating Gamunex-C IV to Prevent Infections in Adults with Immune Deficiency from Blood Cancers
Led by Grifols Biologicals, LLC · Updated on 2026-10-01
49
Participants Needed
5
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This trial focuses on adults with certain immune problems caused by Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma. Researchers are studying whether receiving Gamunex-C through an intravenous infusion every four weeks, along with usual medical care, reduces serious infections over one year. The study is an open-label, multi-center, single-arm trial led by Grifols Biologicals, LLC. Participants will receive 13 doses of Gamunex-C at 500 mgkg via IV infusion starting on Day 1 through Week 48, given once every four weeks. This treatment phase lasts one year, and all participants receive the investigational drug without a comparison group or placebo. The study evaluates the drugs effects alongside standard medical treatment. During the study, participants will be monitored for serious bacterial infections and other related outcomes for the duration of treatment and up to 28 days after the last dose. Assessments include tracking infection rates, antibiotic use, hospitalizations, and safety measures. The total participation time covers the one-year treatment period plus the short post-treatment observation phase.
CONDITIONS
Brief Title
A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
Research Team
J
Judith Wessels-Kranz
M
Marina Acosta Enslen
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here